Core Viewpoint - Rosen Law Firm is reminding investors who purchased PayPal Holdings, Inc. common stock between February 25, 2025, and February 2, 2026, of the April 20, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought PayPal common stock during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is April 20, 2026, with the lead plaintiff representing other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Background - The lawsuit alleges that PayPal's defendants provided misleading information regarding the company's financial targets for 2027 and the growth potential of its Branded Checkout segment [5]. - It is claimed that while presenting an optimistic outlook, the defendants concealed material adverse facts about PayPal's salesforce capabilities, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Nektar Therapeutics securities during the specified Class Period, indicating potential legal issues for the company and its investors [1]. Group 1: Class Action Details - The class action lawsuit is for purchasers of Nektar securities between February 26, 2025, and December 15, 2025 [1]. - Investors who purchased Nektar securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by May 5, 2026, to represent other class members in the litigation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been ranked highly for its performance in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made false or misleading statements regarding the REZOLVE-AA trial, including improper enrollment and overstated trial integrity [5]. - The claims suggest that these misrepresentations led to investor damages when the true details became public [5].

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 4, 2026. SO WHAT: If you purchased Aquestive securities during the Class Peri ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Oracle Corporation common stock between June 12, 2025, and December 16, 2025, of the April 6, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Oracle stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 6, 2026, to serve as lead plaintiff [2]. - The lawsuit alleges that Oracle made false and misleading statements regarding its AI infrastructure strategy, which led to increased capital expenditures without corresponding revenue growth [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, as many firms may lack the necessary experience [3]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [3]. Group 3: Case Specifics - The lawsuit claims that Oracle's increased spending posed risks to its debt, credit rating, and free cash flow, which were not disclosed to investors [4]. - The misrepresentation of Oracle's business operations and prospects is said to have caused investor damages when the true information became public [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Richtech Robotics Inc. during the specified class period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Richtech Robotics securities between January 27, 2026, and January 29, 2026, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 3, 2026 [3]. - The lawsuit alleges that Richtech made false and misleading statements regarding its relationship with Microsoft, which impacted investors when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in the field [4].

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CoreWeave, Inc. (NASDAQ: CRWV) between March 28, 2025 and December 15, 2025, both dates inclusive (the “Class Period”), of the important March 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased CoreWeave securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BlackRock TCP Capital Corp. securities between November 6, 2024, and January 23, 2026, of the upcoming lead plaintiff deadline on April 6, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought BlackRock TCP securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by April 6, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements regarding BlackRock TCP's business and operations, including issues with investment valuations and portfolio restructuring [5]. - Specific claims include that BlackRock TCP's unrealized losses were understated and net asset value was overstated, leading to misleading positive statements about the company's prospects [5].

New York, New York--(Newsfile Corp. - March 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2026.SO WHAT: If you purchased Nektar securities during the Class ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Picard Medical, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Picard Medical securities between September 2, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 13, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements regarding Picard's business and operations, failing to disclose critical adverse facts [5]. - Specific allegations include involvement in a fraudulent stock promotion scheme, insider trading through offshore accounts, and omission of information regarding false rumors affecting stock prices [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Corcept Therapeutics Incorporated during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Corcept common stock between October 31, 2024, and December 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 21, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that during the Class Period, Corcept's defendants misrepresented the strength of clinical trials supporting the New Drug Application (NDA) for relacorilant, claiming it was "powerful support" for FDA approval [5]. - Defendants communicated confidence in the NDA submission and indicated no anticipated obstacles to approval, despite the FDA raising concerns about the clinical evidence [5]. - The lawsuit claims that when the true situation regarding the NDA was revealed, investors suffered damages due to the misrepresentation [5].